Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
Zacks News
Mylan (MYL) to Get CRL Again for Generic Advair from FDA
by Zacks Equity Research
Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.
Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval
by Zacks Equity Research
AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.
Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate
by Zacks Equity Research
Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.
Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why
by Zacks Equity Research
Teva's (TEVA) shares gain 17% in 2018 so far after declining sharply in 2017.
FDA Confirms September Action Date for Teva's Migraine Drug
by Zacks Equity Research
Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.
Should You Hold Momenta (MNTA) Stock in Your Portfolio?
by Zacks Equity Research
Momenta (MNTA) is conducting a strategic review of its ongoing operations as revenues from Glatopa continue to decline.
Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
by Zacks Equity Research
Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.
Company News For May 17, 2018
by Zacks Equity Research
Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B
Eli Lilly's Cluster Headache Candidate Succeeds in Phase III
by Zacks Equity Research
Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.
Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1
by Zacks Equity Research
Teva's (TEVA) shares gain 5% after Warren Buffett's Berkshire Hathaway reveals an increased stake in the company.
Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.
AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.
BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.
Mylan (MYL) Q1 Earnings Lag on Weak North America Sales
by Ekta Bagri
Mylan's first-quarter results were dismal with both earnings and sales missing expectations as challenges in North America persist.
Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline
by Zacks Equity Research
Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.
Mylan (MYL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Investors are exepcted to focus on the performance of EpiPen, newly launched drugs and the progress of the company's biosimilars pipeline when Mylan (MYL) reports results for the Q1.
Teva (TEVA) Stock Dips Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
Teva's (TEVA) shares dip despite first-quarter earnings and sales beat. The company raises its 2018 sales and earnings outlook.
Teva (TEVA) Up on Q1 Earnings & Sales Beat, Rise in Guidance
by Kinjel Shah
Teva's (TEVA) first-quarter earnings and sales beat expectations. The company raises its 2018 sales and earnings outlook. Stock up in pre-market trading.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone is likely to hurt sales of the Specialty segment.
Novartis (NVS) Reports Encouraging Data on MS Candidate
by Zacks Equity Research
Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.
Amgen's Aimovig Reduces Episodic Migraine in 30% Patients
by Zacks Equity Research
Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.
Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug
by Zacks Equity Research
Mylan (MYL) has inked a deal with Israel based Mapi Pharma to acquire its multiple sclerosis candidate.
AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome
by Zacks Equity Research
AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting
BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y
by Zacks Equity Research
BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals